# Clinical Trial to Evaluate the Efficacy and Safety of DW1125 and DW1125A

Study · id `cardio:ct-nct05970679` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05970679](<https://clinicaltrials.gov/study/NCT05970679>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT05970679

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 252 participants.

## Technical summary

Registry record NCT05970679. Randomized; quadruple masking; primary purpose treatment. Start 2022-08-17 (actual); primary completion 2023-04-13 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 252 participants (enrolled count; ClinicalTrials.gov record NCT05970679, source copy `cardio:ctgov-nct05970679-2023-08-01`, retrieved 2026-10-31)
- Started: 2022-08-17 (actual) (ClinicalTrials.gov record NCT05970679, source copy `cardio:ctgov-nct05970679-2023-08-01`, retrieved 2026-10-31)
- Primary completion: 2023-04-13 (actual) (ClinicalTrials.gov record NCT05970679, source copy `cardio:ctgov-nct05970679-2023-08-01`, retrieved 2026-10-31)
- Completion: 2023-04-13 (actual) (ClinicalTrials.gov record NCT05970679, source copy `cardio:ctgov-nct05970679-2023-08-01`, retrieved 2026-10-31)
- Countries: South Korea (ClinicalTrials.gov record NCT05970679, source copy `cardio:ctgov-nct05970679-2023-08-01`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05970679-2023-08-01`, retrieved 2026-10-31)

## The registry's words

- Brief title: Clinical Trial to Evaluate the Efficacy and Safety of DW1125 and DW1125A
- Condition: Hypercholesterolemia, Dyslipidemia
- Intervention (Drug): Ezetimibe/Atorvastatin 10/5 mg
- Intervention (Drug): Atorvastatin 5mg
- Intervention (Drug): Ezetimibe 10mg
- Intervention (Drug): Atorvastatin 10mg
- Intervention (Drug): DW1125 placebo
- Intervention (Drug): DW1125A placebo
- Intervention (Drug): DW1125E placebo
- Intervention (Drug): DW1125A-1 placebo
- Lead sponsor: Daewon Pharmaceutical Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry lists this organization as the lead sponsor: Daewon Pharmaceutical Co., Ltd. (`cardio:org-daewon-pharmaceutical-co-ltd`)

## Provenance

Content hash: fbd0f2245252c69d05e5af40c3535eb7ae511c8629924ae03aef5de028bbf654
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
